The efficacy of chemotherapy combined with endocrine neoadjuvant therapy in HR positive breast cancer
Objective To study and analyze the efficacy of chemotherapy combined with endocrine neoadjuvant therapy in HR positive breast cancer,in order to provide an effective treatment plan for this kind of patients.Method 90 cases of HR positive breast cancer ad-mitted to the hospital from January 2018 to January 2020 were selected as research subjects.They were randomly divided into combined treatment group and control group with 45 cases in each group.The control group was given chemotherapy alone,and the combined treat-ment group was given chemotherapy combined with endocrine therapy.The clinical efficacy,toxicity and side effects,quality of life,re-currence rate,survival rate and PD-1 and PD-L1 expression of the two groups were analyzed.Results The total response rate and PCR rate in the combined treatment group were were higher than those in the control group(P<0.05).The incidence rates of gastrointestinal reaction,liver and kidney function impairment and myelosuppression in the combined treatment group and the control group had no signif-icant differences(P>0.05).The quality of life scores of combined treatment group were higher than those of control group(P<0.05).The recurrence rate of the combined treatment group was lower than that of the control group,and the survival rate was higher than that of the control group(P<0.05).After treatment,the expression rates of PD-1 and PD-L1 in combined treatment group were lower than those in control group(P<0.05).Conclusion Chemotherapy combined with endocrine therapy in HR-positive breast cancer neoadjuvant therapy has good efficacy,can improve the quality of life,improve the prognosis,worthy of popularization.
Breast cancerEstrogen receptorNeoadjuvant chemotherapyNeoadjuvant endocrine therapyAnti HER-2 targeted therapy
NETL
NSTL
万方数据
